7R90 Stock Overview
A clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Qualigen Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.63 |
| 52 Week High | US$24.63 |
| 52 Week Low | US$2.53 |
| Beta | 0.15 |
| 1 Month Change | 0% |
| 3 Month Change | -55.88% |
| 1 Year Change | -89.43% |
| 3 Year Change | -99.38% |
| 5 Year Change | n/a |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7R90 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -2.6% |
| 1Y | -89.4% | -14.7% | 6.9% |
Return vs Industry: 7R90 underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 7R90 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 7R90 volatility | |
|---|---|
| 7R90 Average Weekly Movement | 71.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7R90's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7R90's weekly volatility has increased from 37% to 72% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 4 | Kevin Richardson | www.qlgntx.com |
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.
Qualigen Therapeutics, Inc. Fundamentals Summary
| 7R90 fundamental statistics | |
|---|---|
| Market cap | €2.75m |
| Earnings (TTM) | -€7.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 7R90 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7R90 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$2.55m |
| Gross Profit | -US$2.55m |
| Other Expenses | US$5.31m |
| Earnings | -US$7.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -67.0% |
How did 7R90 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 14:33 |
| End of Day Share Price | 2024/11/04 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Qualigen Therapeutics, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Bautz | Zacks Small-Cap Research |